30 March 2016 - CADTH has received notice of a pending submission from Boehringer Ingelheim for empagliflizin (Jardiance) for use by patients with type 2 diabetes mellitus with a high cardiovascular risk.

The submission is due on 27 April 2016.

For more details, go to: https://www.cadth.ca/jardiance